Last edition
News about "Vivtex to Develop Oral Obesity Therapies"
Novo Nordisk Signs USD 2.1 Billion Pact with Vivtex to Develop Oral Obesity Therapies
Novo Nordisk has entered into a strategic collaboration with US-based Vivtex to develop next-generation oral biologic therapies for obesity, diabetes and related metabolic conditions.
Vivtex To Develop Oral Obesity Therapies | 27/02/2026 | By Darshana | 116
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members